| Lung and colon cancer histopathological image dataset (lc25000) AA Borkowski, MM Bui, LB Thomas, CP Wilson, LA DeLand, ... arXiv preprint arXiv:1912.12142, 2019 | 371 | 2019 |
| Loss of caspase-1 and caspase-3 protein expression in human prostate cancer RN Winter, A Kramer, A Borkowski, N Kyprianou Cancer research 61 (3), 1227-1232, 2001 | 322 | 2001 |
| p53 protein accumulates frequently in early bronchial neoplasia WP Bennett, TV Colby, WD Travis, A Borkowski, RT Jones, DP Lane, ... Cancer research 53 (20), 4817-4822, 1993 | 319 | 1993 |
| bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer TJ Mackey, A Borkowski, P Amin, SC Jacobs, N Kyprianou Urology 52 (6), 1085-1090, 1998 | 273 | 1998 |
| Loss of the cyclin-dependent kinase inhibitor p27 (Kip1) protein in human prostate cancer correlates with tumor grade. Y Guo, GN Sklar, A Borkowski, N Kyprianou Clinical cancer research: an official journal of the American Association …, 1997 | 269 | 1997 |
| Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia N KYPRIANOU, JP LITVAK, A BORKOWSKI, R ALEXANDER, ... The Journal of urology 159 (6), 1810-1815, 1998 | 214 | 1998 |
| alpha1-ADRENOCEPTOR ANTAGONISTS TERAZOSIN AND DOXAZOSIN INDUCE PROSTATE APOPTOSIS WITHOUT AFFECTING CELL PROLIFERATION IN … JK Chon, A Borkowski, AW Partin, JT Isaacs, SC Jacobs, N Kyprianou The Journal of urology 161 (6), 2002-2008, 1999 | 203 | 1999 |
| Loss of cell cycle regulators p27Kip1 and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival JJ Del Pizzo, A Borkowski, SC Jacobs, N Kyprianou The American journal of pathology 155 (4), 1129-1136, 1999 | 149 | 1999 |
| Incidence of apoptosis and cell proliferation in prostate cancer: Relationship with TGF‐β1 and bcl‐2 expression H Tu, SC Jacobs, A Borkowski, N Kyprianou International journal of cancer 69 (5), 357-363, 1996 | 143 | 1996 |
| Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor‐β expression in benign prostatic hyperplasia DT Glassman, JK Chon, A Borkowski, SC Jacobs, N Kyprianou The prostate 46 (1), 45-51, 2001 | 107 | 2001 |
| Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non–small cell lung carcinoma L Burke, DB Flieder, DG Guinee, E Brambilla, AN Freedman, WP Bennett, ... Clinical cancer research 11 (1), 232-241, 2005 | 88 | 2005 |
| Using artificial intelligence for COVID-19 chest X-ray diagnosis AA Borkowski, NA Viswanadhan, LB Thomas, RD Guzman, LA Deland, ... Federal Practitioner 37 (9), 398, 2020 | 82 | 2020 |
| Integrity of p53 in hepatitis B x antigen-positive and-negative hepatocellular carcinomas MS Greenblatt, MA Feitelson, M Zhu, WP Bennett, JA Welsh, R Jones, ... Cancer research 57 (3), 426-432, 1997 | 82 | 1997 |
| Review of recent placebo‐controlled trials utilizing phytotherapeutic agents for treatment of BPH FC Lowe, K Dreikorn, A Borkowski, J Braeckman, L Denis, P Ferrari, ... The Prostate 37 (3), 187-193, 1998 | 75 | 1998 |
| p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. WP Bennett, WS El-Deiry, WL Rush, DG Guinee Jr, AN Freedman, ... Clinical cancer research: an official journal of the American Association …, 1998 | 75 | 1998 |
| Esophagin and proliferating cell nuclear antigen (PCNA) are biomarkers of human esophageal neoplastic progression MC Kimos, S Wang, A Borkowski, GY Yang, CS Yang, K Perry, A Olaru, ... International journal of cancer 111 (3), 415-417, 2004 | 68 | 2004 |
| Racial differences in prostate cancer growth: apoptosis and cell proliferation in Caucasian and African‐American patients Y Guo, DB Sigman, A Borkowski, N Kyprianou The Prostate 42 (2), 130-136, 2000 | 64 | 2000 |
| Other medical therapies K Dreikorn, F Lowe, A Borkowski, C Buck, J Braeckman, D Chopin, ... Proceedings of the 5th international consultation on benign prostatic …, 2001 | 62 | 2001 |
| Revolutionizing digital pathology with the power of generative artificial intelligence and foundation models A Waqas, MM Bui, EF Glassy, I El Naqa, P Borkowski, AA Borkowski, ... Laboratory Investigation, 100255, 2023 | 55 | 2023 |
| Reduction of human prostate tumor vascularity by the α1‐adrenoceptor antagonist terazosin K Keledjian, A Borkowski, G Kim, JT Isaacs, SC Jacobs, N Kyprianou The Prostate 48 (2), 71-78, 2001 | 53 | 2001 |
Natasha KyprianouProfessor of Urology, Oncological Sciences and Pathology, Icahn School of Medicine at Mount Sinai在 mountsinai.org 的电子邮件经过验证
